Poisoning and Toxic Effects of Drugs with MCC: Inpatient Reimbursement Overview

DRG 917 encompasses inpatient admissions for poisoning and toxic effects of drugs when a Major Complication or Comorbidity is present, reflecting higher clinical complexity. This matters for inpatient reimbursement because the Major Complication or Comorbidity designation drives greater resource intensity and influences payment under Medicare.

Customize your policy alerts

Sign up for drg 917 policy alerts

Get alerted when payer policies referencing 917 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 917 Overview

DRG 917 covers hospital admissions for poisoning and toxic effects of drugs complicated by a Major Complication or Comorbidity. Typical cases include severe adverse drug reactions, intentional or unintentional overdoses, and toxic exposures requiring intensive monitoring or interventions. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity substantially increases resource use and affects reimbursement classification. Accurate documentation of the toxic agent and the severity-related complications is central to correct inpatient payment assignment.

Clinical Trials

Acute resuscitation and antidote efficacy trials: randomized or pragmatic studies that evaluate time-sensitive emergency interventions, administration protocols, or newly developed antidotes in hospitalized patients presenting with severe drug poisoning and toxic effects with major complications (eg, respiratory failure, hemodynamic instability, or coma). These studies focus on the emergency and ICU phase of care, enrolling adults and sometimes pediatrics who require advanced airway management, vasopressors, or multi-organ support, and compare outcomes such as mortality, organ failure progression, and duration of intensive care. Results are directly relevant to clinicians and payers because they inform protocols that can shorten ICU stays, reduce complication rates, and allocate high-cost rescue therapies more effectively.
Comparative effectiveness and dosing strategy studies in complex polypharmacy or chronic-exposure populations: observational cohort studies or randomized comparative trials that examine different management strategies (eg, decontamination methods, stepwise detoxification protocols, or dosing regimens for reversal agents) among hospitalized patients with poisoning from prescription medications, illicit substances, or occupational exposures, often in patients with comorbidities like hepatic or renal impairment. These trials target subgroups at high risk for major complications to determine which approaches reduce progression to MCC status, readmission risk, and resource utilization. For providers and payers, this research helps identify cost-effective care pathways and patient selection criteria that can prevent escalation to more expensive critical-care resources.
Post-discharge outcomes, rehabilitation, and health-services research: prospective cohort studies and health-systems trials that follow survivors of poisoning with major complications after hospital discharge to evaluate functional recovery, neurocognitive outcomes, adherence to follow-up substance-use or psychiatric treatment, and rates of readmission or long-term healthcare utilization. These research efforts often include interventions such as structured discharge planning, linkage to outpatient addiction or mental health services, and case-management models, and enroll patients who required ICU care or had prolonged hospitalizations. Findings guide payers and health systems on investments in transitional care and community-based services that may reduce readmissions, improve long-term outcomes, and lower total cost of care for this high-risk DRG.

Wound Debridements for Injuries with MCC: Inpatient Reimbursement Overview

902-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-CC

Wound Debridements for Injuries with CC: Inpatient Reimbursement Overview

903-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITHOUT-CC-MCC

Wound Debridements for Injuries without CC/MCC: Inpatient Reimbursement Overview

904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

905-SKIN-GRAFTS-FOR-INJURIES-WITHOUT-CC-MCC

Skin Grafts for Injuries without CC/MCC: Inpatient Reimbursement Overview

906-HAND-PROCEDURES-FOR-INJURIES

Hand Procedures for Injuries: Inpatient Reimbursement Overview

907-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-MCC

Other O.R. Procedures for Injuries with MCC: Inpatient Reimbursement Overview

908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

909-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITHOUT-CC-MCC

Other O.R. Procedures for Injuries without CC/MCC: Inpatient Reimbursement Overview

913-TRAUMATIC-INJURY-WITH-MCC

Traumatic Injury with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 19

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical Trials

Acute resuscitation and antidote efficacy trials: randomized or pragmatic studies that evaluate time-sensitive emergency interventions, administration protocols, or newly developed antidotes in hospitalized patients presenting with severe drug poisoning and toxic effects with major complications (eg, respiratory failure, hemodynamic instability, or coma). These studies focus on the emergency and ICU phase of care, enrolling adults and sometimes pediatrics who require advanced airway management, vasopressors, or multi-organ support, and compare outcomes such as mortality, organ failure progression, and duration of intensive care. Results are directly relevant to clinicians and payers because they inform protocols that can shorten ICU stays, reduce complication rates, and allocate high-cost rescue therapies more effectively.
Comparative effectiveness and dosing strategy studies in complex polypharmacy or chronic-exposure populations: observational cohort studies or randomized comparative trials that examine different management strategies (eg, decontamination methods, stepwise detoxification protocols, or dosing regimens for reversal agents) among hospitalized patients with poisoning from prescription medications, illicit substances, or occupational exposures, often in patients with comorbidities like hepatic or renal impairment. These trials target subgroups at high risk for major complications to determine which approaches reduce progression to MCC status, readmission risk, and resource utilization. For providers and payers, this research helps identify cost-effective care pathways and patient selection criteria that can prevent escalation to more expensive critical-care resources.
Post-discharge outcomes, rehabilitation, and health-services research: prospective cohort studies and health-systems trials that follow survivors of poisoning with major complications after hospital discharge to evaluate functional recovery, neurocognitive outcomes, adherence to follow-up substance-use or psychiatric treatment, and rates of readmission or long-term healthcare utilization. These research efforts often include interventions such as structured discharge planning, linkage to outpatient addiction or mental health services, and case-management models, and enroll patients who required ICU care or had prolonged hospitalizations. Findings guide payers and health systems on investments in transitional care and community-based services that may reduce readmissions, improve long-term outcomes, and lower total cost of care for this high-risk DRG.

Wound Debridements for Injuries with MCC: Inpatient Reimbursement Overview

902-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-CC

Wound Debridements for Injuries with CC: Inpatient Reimbursement Overview

903-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITHOUT-CC-MCC

Wound Debridements for Injuries without CC/MCC: Inpatient Reimbursement Overview

904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

905-SKIN-GRAFTS-FOR-INJURIES-WITHOUT-CC-MCC

Skin Grafts for Injuries without CC/MCC: Inpatient Reimbursement Overview

906-HAND-PROCEDURES-FOR-INJURIES

Hand Procedures for Injuries: Inpatient Reimbursement Overview

907-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-MCC

Other O.R. Procedures for Injuries with MCC: Inpatient Reimbursement Overview

908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

909-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITHOUT-CC-MCC

Other O.R. Procedures for Injuries without CC/MCC: Inpatient Reimbursement Overview

913-TRAUMATIC-INJURY-WITH-MCC

Traumatic Injury with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 19

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Poisoning and Toxic Effects of Drugs with MCC: Inpatient Reimbursement Overview

Sign up for drg 917 policy alerts

DRG 917 Overview

Poisoning and Toxic Effects of Drugs with MCC: Inpatient Reimbursement Overview

Sign up for drg 917 policy alerts

DRG 917 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References